07/10/2014 - 17:01
MADRID – The investigational neurokinin-1 receptor antagonist rolapitant met all of its endpoints in the prevention of chemotherapy-induced nausea and vomiting in a phase III trial.
Among 532...
Field of Interest: Oncology
News Feed: Internal Medicine News - Oncology